Rituximab 과민반응 환자에서의 단일 농도 탈감작 프로토콜과 단계별 희석 탈감작 프로토콜의 비교
Comparison of one-bag and multibag desensitization protocols for the prevention of rituximab hypersensitivity
4
조회
0
다운로드
3
인용
0
참고문헌
키워드
초록
Purpose: Rituximab is prone to infusion-related reactions, which commonly requires desensitization to maintain its administration. Conventional desensitization protocols are using multistep infusion by diluting solutions. However, the process of diluting drugs and stepwise delivery needs additional time and effort. The objective of this study was to investigate the safety and efficacy of a nondiluting, one-bag protocol of rituximab desensitization. Methods: A retrospective study was performed by reviewing the medical records of patients who underwent rituximab desensitization between 2009 and 2018. The completion rate, occurrence and severity of breakthrough reactions (BTR), and time required to complete the therapy were compared between one-bag protocol and multibag protocol. Results were analyzed by generalized estimation equation method, and odds ratios (ORs) of completion rate and BTR incidence were estimated. Results: Total 190 cases of desensitization therapy were performed in 49 patients; the incidence of BTR was 16.84% and the overall completion rate was 96.32%. No significant difference in completion rate was found (OR, 3.58; 95% confidence interval [CI], 0.79–16.38) and there was no significant difference in BTR incidence (OR, 0.81; 95% CI, 0.23–2.82) in one-bag protocol. BTR in the one-bag protocol tended to occur even through entire steps, whereas most of the BTR in the multibag protocol occurred at later steps of the process. The average time spent in the desensitization was 60 minutes shorter in the one-bag than the multibag protocol (258.15 minutes vs. 329.81 minutes, P<0.001). Conclusion: One-bag desensitization protocol showed no significant difference in safety and efficiency compared to the conventional multibag protocol, with shortening the time required for completion.
Abstract
Purpose: Rituximab is prone to infusion-related reactions, which commonly requires desensitization to maintain its administration. Conventional desensitization protocols are using multistep infusion by diluting solutions. However, the process of diluting drugs and stepwise delivery needs additional time and effort. The objective of this study was to investigate the safety and efficacy of a nondiluting, one-bag protocol of rituximab desensitization. Methods: A retrospective study was performed by reviewing the medical records of patients who underwent rituximab desensitization between 2009 and 2018. The completion rate, occurrence and severity of breakthrough reactions (BTR), and time required to complete the therapy were compared between one-bag protocol and multibag protocol. Results were analyzed by generalized estimation equation method, and odds ratios (ORs) of completion rate and BTR incidence were estimated. Results: Total 190 cases of desensitization therapy were performed in 49 patients; the incidence of BTR was 16.84% and the overall completion rate was 96.32%. No significant difference in completion rate was found (OR, 3.58; 95% confidence interval [CI], 0.79–16.38) and there was no significant difference in BTR incidence (OR, 0.81; 95% CI, 0.23–2.82) in one-bag protocol. BTR in the one-bag protocol tended to occur even through entire steps, whereas most of the BTR in the multibag protocol occurred at later steps of the process. The average time spent in the desensitization was 60 minutes shorter in the one-bag than the multibag protocol (258.15 minutes vs. 329.81 minutes, P<0.001). Conclusion: One-bag desensitization protocol showed no significant difference in safety and efficiency compared to the conventional multibag protocol, with shortening the time required for completion.
참고문헌 (20)
- Maloney DG, "IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma", Blood, 90, pp.2188~2195 (1997)
- Grillo-López AJ, "Overview of the clinical development of rituximab : first monoclonal antibody approved for the treatment of lymphoma", Semin Oncol, 26(5 Suppl 14), pp.66~73 (1999)
- Bingham CO 3rd, "Immunization responses in rheumatoid arthritis patients treated with rituximab : results from a controlled clinical trial", Arthritis Rheum, 62, pp.64~74 (2010)
- Stone JH, "Rituximab versus cyclophosphamide for ANCA-associated vasculitis", N Engl J Med, 363, pp.221~232 (2010)
- Paul F, "Infusion-related reactions to rituximab : frequency, mechanisms and predictors", Expert Rev Clin Immunol, 15, pp.383~389 (2019)
- Galvão VR, "Hypersensitivity to biological agents-updated diagnosis, management, and treatment", J Allergy Clin Immunol Pract, 3, pp.175~185 (2015)
- Mezzano V, "Drug desensitization in the management of hypersensitivity reactions to monoclonal antibodies and chemotherapy", BioDrugs, 28, pp.133~144 (2014)
- Castells MC, "Anaphylaxis to chemotherapy and monoclonal antibodies", Immunol Allergy Clin North Am, 35, pp.335~348 (2015)
- Chung SJ, "A new non-dilution rapid desensitization protocol successfully applied to all-grade platinum hypersensitivity", Cancer Chemother Pharmacol, 82, pp.777~785 (2018)
- Lee JH, "A one-bag rapid desensitization protocol for paclitaxel hypersensitivity : a noninferior alternative to a multi-bag rapid desensitization protocol", J Allergy Clin Immunol Pract, 8, pp.696~703 (2020)
- Castells MC, "Hypersensitivity reactions to chemotherapy : outcomes and safety of rapid desensitization in 413 cases", J Allergy Clin Immunol, 122, pp.574~580 (2008)
- Lebel E, "Hypersensitivity reactions to rituximab : 53 successful desensitizations in 7 patients with severe, near-fatal reactions", J Allergy Clin Immunol Pract, 4, pp.1000~1002 (2016)
- Shah SR, "Desensitization therapy using ‘Mariana Castells’ protocol in a patient with multiple autoimmune disorders- does it work?", J Community Hosp Intern Med Perspect, 9, pp.53~54 (2019)
- Vidal C, "A modified protocol for rapid desensitization to chemotherapy agents", J Allergy Clin Immunol Pract, 4, pp.1003~1005 (2016)
- Zhang Y, "Stability of stock and diluted rituximab", Am J Health Syst Pharm, 70, pp.436~438 (2013)
- Pérez-Rodríguez E, "Outcome of 490 desensitizations to chemotherapy drugs with a rapid one-solution protocol", J Allergy Clin Immunol Pract, 6, pp.1621~1627.e6 (2018)
- Brennan PJ, "Hypersensitivity reactions to mAbs : 105 desensitizations in 23 patients, from evaluation to treatment", J Allergy Clin Immunol, 124, pp.1259~1266 (2009)
- Brown SG, "Clinical features and severity grading of anaphylaxis", J Allergy Clin Immunol, 114, pp.371~376 (2004)
- de Las Vecillas Sánchez L, "Drug hypersensitivity and desensitizations : mechanisms and new approaches", Int J Mol Sci, 18, pp.1316~ (2017)